Methods and pharmaceutical compositions for the treatment of fibrosis

Abstract

The present invention relates to methods, and pharmaceutical compositions for the treatment of fibrosis. In particular, the present invention relates to a method of treating fibrosis in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one monoacylglycerol lipase (MGL) inhibitor.

1 . A method of treating fibrosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one monoacylglycerol lipase (MGL) inhibitor. 
     
     
         2 . The method of  claim 1  wherein the fibrosis affects at least one organ selected from the group consisting of skin, heart, liver, lung, and kidney. 
     
     
         3 . The method of  claim 1  wherein the fibrosis is selected from the group consisting of dermal scar formation, keloids, liver fibrosis, lung fibrosis, kidney fibrosis, glomerulosclerosis, pulmonary fibrosis, liver fibrosis, renal fibrosis, intestinal fibrosis, interstitial fibrosis, cystic fibrosis of the pancreas and lungs, injection fibrosis, endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, and nephrogenic systemic fibrosis. 
     
     
         4 . The method of  claim 1  wherein the fibrosis is liver fibrosis. 
     
     
         5 . The method of  claim 1  wherein the fibrosis is inflammation-induced fibrosis.